logo-loader

Full interview: Canntab receives indication of patentability for its release cannabidiol formulation

Published: 17:38 15 Aug 2019 EDT

Canntab Therapeutics (CSE:PILL.CN-OTCQX: CTABF) Chief Financial Officer Richard Goldstein joined Steve Darling from Proactive Investors Vancouver on Skype with news that the company has received an initial assessment from the Geneva-based International Preliminary Report on Patentability regarding their Immediate Release Cannabidiol Formulation.


Goldstein talks about what that means for the company going forward and how this fall will be a defining moment for the company. 
 

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

9 hours, 2 minutes ago